Rising Liver Disease Cases Fueling The Growth Of The Market Due To Increasing Obesity-Linked Non-Alcoholic Fatty Liver Disease (NAFLD) Cases Is Supporting Development Across The Human Serum Albumin Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Expansion Is Expected For The Human Serum Albumin Market Over The Forecast Period?

The human serum albumin market has demonstrated substantial growth over recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, registering a compound annual growth rate (CAGR) of 7.3%. This past growth can be attributed to factors such as the constrained availability of recombinant HSA, the ongoing reliance on plasma-derived HSA, increasing demand from hospitals and clinical settings, its rising application in diagnostic and therapeutic procedures, and the adoption of standard injection solutions.

The human serum albumin market is anticipated to experience robust growth in the coming years. It is projected to expand to $8.16 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is driven by factors such as the development of yeast, bacterial, and plant-based recombinant hsa, an increasing demand for fatty acid-free formulations, the widening application in drug delivery and nutrition enhancement, greater investment in research laboratories, and increased procurement by hospitals and blood banks. Prominent trends observed in this period include a rising demand for both plasma-derived and recombinant human serum albumin, an expanded use of hsa in volume expanders and drug delivery systems, growing adoption of lyophilized powder and injection solutions, the expansion of applications in hospital and research laboratories, and a focus on fatty acid-free and specialty hsa preparations.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Which Strategic Drivers Are Supporting The Human Serum Albumin Market Development?

The growing incidence of liver ailments is anticipated to drive expansion in the human serum albumin market. These conditions encompass various disorders that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases stems from the increasing rates of obesity, given that excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), which can result in fat buildup, inflammation, and eventual liver failure. Human serum albumin aids in managing liver disease by restoring blood volume, minimizing fluid retention, safeguarding kidney function, and enhancing prognoses in related complications like ascites and hepatorenal syndrome. As an illustration, a report issued in December 2024 by the Office for Health Improvement and Disparities, a UK government agency, indicated a 3.6% rise in premature fatalities from alcoholic liver disease in 2023, totaling 5,984 cases against 5,776 in 2022. Consequently, the escalating occurrence of liver conditions is fueling the expansion of the human serum albumin market.

Which Segment Groups Define The Human Serum Albumin Market Landscape?

The human serum albumin market covered in this report is segmented –

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

What Trends Are Driving Changes In The Human Serum Albumin Market?

Major companies in the human serum albumin market are concentrating on developing innovative solutions, such as animal-free recombinant excipients, to boost product safety, scalability, and adherence to regulatory standards in biomanufacturing applications. An animal-free recombinant excipient refers to a biologically engineered inactive substance created using recombinant DNA technology without any animal or human-derived components, ensuring high purity and safety in pharmaceutical and biomanufacturing applications. For instance, in April 2025, InVitri Inc., a US-based provider of animal-free, recombinant proteins and excipients, launched Optibumin 25, the first recombinant 25% human serum albumin for closed-system biomanufacturing. This product is the first recombinant 25% human serum albumin specifically designed for closed-system biomanufacturing. It is optimized for downstream processing, formulation, and cryopreservation workflows, and is currently available in 100 mL single-use bags. With its animal-origin-free and chemically defined composition, it ensures high purity, consistency, and reduced contamination risks. It is GMP-ready, scalable to commercial production volumes, and offers a stable, sterile solution that integrates seamlessly into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Which Companies Are Engaged In The Human Serum Albumin Market Environment?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Access The Complete Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

What Is The Largest Regional Market In The Human Serum Albumin Market?

North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Human Serum Albumin Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company

Wall Decor Market Report 2026

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Market Report 2026

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Market Report 2026

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795